Literature DB >> 10080933

Combinatorial chemistry reveals a new motif that binds the platelet fibrinogen receptor, gpIIbIIIa.

D S Thorpe1, H Yeoman, A W Chan, V Krchnak, M Lebl, S Felder.   

Abstract

Among cell adhesion molecules, the classic Arg-Gly-Asp (RGD) motif is the best studied. We used combinatorial chemical and affinity immunochemical methods to find a novel motif of unnatural peptide ligands for the fibrinogen receptor of platelets, gpIIbIIIa (alphaIIbbeta3). The new d-amino acid motif, p(f/y)l, is unique among the ligands that bind the RGD pocket: It lacks the carboxylic acid group that is believed to coordinate with calcium in the MIDAS motif of the receptor. With an IC50 of 14 microM for the most potent compound, these linear p(f/y)l peptides had affinities similar to those of linear peptides containing RGD, and reversed sequences failed to compete with binding up to 1 mM. As the new motif was so different, molecular modeling was employed to suggest a model for molecular recognition. A reversed binding mechanism common for d-amino acid mimics of natural l-amino acid peptides offers an attractive hypothesis that suggests three points of contact similar to those made by the RGD-mimicking monoclonal antibody, OPG2. Interestingly, the model proposes that pi-electrons in the new motif may substitute for the carboxylate group present in all other RGD-types of ligands. Although modeling linear peptides is subjective, the pi-bonding model provides intriguing possibilities for medicinal chemistry after appropriate confirmatory studies. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080933     DOI: 10.1006/bbrc.1999.0374

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  Combinatorial approaches to inhibitors of VLA-4: piperazine-peptoid-bisarylureas.

Authors:  I Lewis; B Rohde; M Mengus; M Weetall; S Maida; R Hugo; P Lake
Journal:  Mol Divers       Date:  2000       Impact factor: 2.943

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.